Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Sacituzumab tirumotecan(biological)

Enrollment

520 target

Eligibility

18 years · All sexes

Timeline

2024 – 2030

Study locations (30)

• Kaiser Permanente - Oakland ( Site 0054), Oakland, California, United States
• Kaiser Permanente - Roseville ( Site 0055), Roseville, California, United States
• Kaiser Permanente - San Francisco ( Site 0056), San Francisco, California, United States
• Kaiser Permanente - Santa Clara ( Site 0057), Santa Clara, California, United States
• Kaiser Permanente-Kaiser Permanente ( Site 0036), Vallejo, California, United States
• Kaiser Permanente - Walnut Creek ( Site 0058), Walnut Creek, California, United States
• Mid Florida Hematology and Oncology Center ( Site 0005), Orange City, Florida, United States
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003), Marietta, Georgia, United States
• University of Michigan ( Site 0009), Ann Arbor, Michigan, United States
• Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051), Springfield, Missouri, United States
• Astera Cancer Care ( Site 0032), East Brunswick, New Jersey, United States
• Stony Brook University-Cancer Center ( Site 0038), Stony Brook, New York, United States
• Sanford Fargo Medical Center ( Site 0028), Fargo, North Dakota, United States
• Sanford Cancer Center ( Site 0024), Sioux Falls, South Dakota, United States
• John Peter Smith Hospital ( Site 0065), Fort Worth, Texas, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE3NCT07185997
  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  ArriVent BioPharma, Inc.

See all trials for Small cell lung cancer →